ASCO GI: Biologic Helps in Esophageal Cancer (CME/CE)
SAN FRANCISCO (MedPage Today) — Three-fourths of patients with advanced esophageal cancer had major responses when cetuximab (Erbitux) was added to chemoradiation, investigators reported here.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com